Salute e Benessere

Pneumococcal Vaccine Market Witnesses Steady Growth with a CAGR of 5.3%…

Meningococcal disease is caused by bacteria called as Neisseria meningitidis and includes infection of spinal cord, brain lining and bloodstream. It usually spreads from nearby infected areas such as the nasal sinuses or from the cerebrospinal fluid. Meningococcal disease is caused by bacteria called as Neisseria meningitidis and includes infection of spinal cord, brain lining and bloodstream. It usually spreads from nearby infected areas such as the nasal sinuses or from the cerebrospinal...
PR Newswire
17/05/2023

Philips announces exchange ratio for 2022 dividend

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG; AEX: PHIA) today announced that the exchange ratio for the dividend for the year 2022 is 1 new common share for every 22.3906 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 11, 12 and 15, 2023, of EUR 19.0020 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of...
Nasdaq GlobeNewswire
17/05/2023

Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley Annual Sustainable Finance Summit on May 22, 2023.Alvotech is scheduled to hold a fireside chat on May 22, 2023 at 10:15 am ET and will host investor meetings at the conference.Alvotech is committed to the promise of biosimilars, which expand patient access to medicines globally and...
Nasdaq GlobeNewswire
17/05/2023

Invitation to Immunovia's Q1 presentation

Telephone numbers and webcast Telephone numbers and webcast Call any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Sweden : +46 (0)8 5051 0031United Kingdom : +44 (0) 207 107 06 13United States : +1 (1) 631 570 56 13 Link to the webcast: https://access.creomediamanager.com/registration/058aa458-36d2-4352-9dbf-1894dc75828d?ref=https%3A%2F%2Fcreo-live.creomediamanager.com%2F058aa458-36d2-4352-9dbf-1894dc75828d...
PR Newswire
17/05/2023

Cleanroom Technology Market to be Worth $5.6 Billion by 2030: Grand View…

Read 208-page market research report, "Cleanroom Technology Market Size, Share & Trends Analysis Report By Product (Consumables, Equipment), By End-use, By Region, And Segment Forecast, 2023 - 2030", published by Grand View Research. Read 208-page market research report, " Cleanroom Technology Market Size, Share & Trends Analysis Report By Product (Consumables, Equipment), By End-use, By Region, And Segment Forecast, 2023 - 2030 ", published by Grand View Research…
PR Newswire
17/05/2023

DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT…

With its Debio 0123 WEE1 inhibitor, Debiopharm is seeking to meet the urgent need for novel treatment interventions to improve clinical outcomes and quality of life for patients suffering from newly diagnosed or recurrent GBM. In cancer cells, DDR pathways are often upregulated due to genomic instability, elevating the chances of resistance to DNA-damaging therapies. Therefore, blocking DNA repair pathways through inhibition of essential kinases such as WEE1 might contribute to increase the…
PR Newswire
17/05/2023

Cemplicity helps NHS Sussex further expand its Patient Reported Measures…

A pivotal development of the pilot is introducing a strong equity lens to the Sussex approach, further supporting the four main statutory purposes of Integrated Care Systems (ICSs) in the UK. These purposes are highlighted in the recently published Hewitt Review. A pivotal development of the pilot is introducing a strong equity lens to theSussexapproach, further supporting the four main statutory purposes of Integrated Care Systems (ICSs) in the UK. These purposes are highlighted in the...
PR Newswire
17/05/2023

VIVUS' QSIVA in Combination with a Digital Lifestyle Intervention Leads to…

— Poster presented at the 30 thEuropean Congress on Obesity (ECO 2023) shows addition of QSIVA provides benefits compared with Digital Lifestyle Intervention (DLI) alone in improving health outcomes in adults with obesity —AMSTERDAM, Netherlands, May17, 2023(GLOBE NEWSWIRE) -- VIVUS BV, the European affiliate of VIVUS LLC (“ VIVUS ”), a biopharmaceutical company, today announced the results of a clinical study ( NCT04408586 ) demonstrating that QSIVA (phentermine and topiramate...
Nasdaq GlobeNewswire
17/05/2023

Philips launches AI-powered CT system to accelerate routine radiology and…

New Philips CT 3500 increases return on investment by meeting the throughput and uptime needs of routine radiology and high-volume screening programs AI-powered workflow and image reconstruction enhance productivity and first-time-right imaging Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the Philips CT 3500, a new high-throughput CT system targeting the needs of routine radiology and...
Nasdaq GlobeNewswire
17/05/2023

New Expert Guidelines from IWGDF Highlight the Growing International Recognition…

New IWDGF GuidelinesThe International Working Group on the Diabetic Foot (IWGDF) has just published its 2023 Guidelines. This set of recommended DFU interventions, developed by a panel of renowned experts, serves as a trusted resource for healthcare professionals worldwide. New IWDGF GuidelinesTheInternational Working Group on the Diabetic Foot (IWGDF)has just published its 2023 Guidelines. This set of recommended DFU interventions, developed by a panel of renowned experts, serves as a...
PR Newswire
17/05/2023

Askel Healthcare has appointed globally renowned orthopedic surgeons and sports…

The Clinical Advisory Board consists of internationally recognized specialists in the treatment of cartilage damage. The Board is chaired by a Swedish professor, Mats Brittberg (MD), an orthopedic surgeon and an award-winning honorary member of the International Cartilage Regeneration and Joint Preservation Society (ICRS) and one of the world's most recognized researchers in knee cartilage repair. The Clinical Advisory Board consists of internationally recognized specialists in the treatment…
PR Newswire
17/05/2023

Sania Therapeutics launches to advance novel medicines for neural circuit…

Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction Sania emerges from stealth mode and presentskey proof-of-concept data at ASGCT 2023Launchingcore technology platforms which enablethe precision delivery of proteins for neuromodulationTeam combines world-leading scientific pioneers with industry drug development expertiseLONDON, UK & NEW YORK, USA – 17 May 2023, Sania Therapeutics (the “Company”),...
Nasdaq GlobeNewswire
17/05/2023

BioSenic reacquires global IP rights and provides update on JTA-004 development

INSIDE INFORMATION BioSenic plans to further develop its program on an active injectable viscosupplement JTA, combining anti-pain and anti-inflammatory characteristics on a subtype of knee osteoarthritis.Mont-Saint-Guibert, Belgium, May 17th , 2023 7 .00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces an update to its future plans...
Nasdaq GlobeNewswire
17/05/2023

Roche showcases commitment to advancing innovative diagnostic solutions at…

"Laboratories have a unique opportunity to connect siloed data across systems and points of care for greater insights," said Moritz Hartmann, Head of Roche Information Solutions at Roche Diagnostics. "At Roche, we are working closely together with lab leaders to enable more patient-centred care. Our navify®portfolio of integrated digital solutions enables open digital ecosystems that connect to innovations, drive operational efficiencies and generate actionable insights for…
PR Newswire
17/05/2023

Roche's BTK inhibitor fenebrutinib significantly reduced brain lesions in people…

Fenebrutinib is an investigational, potent and highly selective oral Bruton's tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase II study met its primary and secondary endpoints by reducing the total number of new gadolinium-enhancing T1 brain lesions and significantly reducing the total number of new or enlarging T2 brain lesions compared to placeboThe safety profile of fenebrutinib was consistent...
Nasdaq GlobeNewswire
17/05/2023

IBA Business Update – First Quarter 2023

Louvain-la-Neuve, Belgium, 17 May 2023- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter ending 31 March 2023.Group Overview Strong balance sheet maintained with EUR 103 million net cash positionContinued focus on delivering EUR 1.3 billion Group backlog, with close to 65 equipment projects under installation in 2023Investment plan on track with R&D and digital initiatives to...
Nasdaq GlobeNewswire
17/05/2023

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress…

Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an investigational drug in Alagille syndrome and an approved medicine in PFIC, with evidence of rapid, sustained, and significant improvements in pruritus and sleep, and reductions in serum bile acids (sBAs) Further data shows evidence of disease modification with longer-term native liver survival in...
Nasdaq GlobeNewswire
17/05/2023

Soocas Announces Neos on Kickstarter, a Revolutionary Dual-Action Brushing and…

The flossing and brushing combo help to remove 40 times more dental plaque, increase dental gap cleaning by over 10 times, and efficiently whiten teeth 2 times more compared to a manual toothbrush. The flossing and brushing combo help to remove 40 times more dental plaque, increase dental gap cleaning by over 10 times, and efficiently whiten teeth 2 times more compared to a manual toothbrush. The patented FlowPulse Pump applies water pressure forming pulsating water flow through the...
PR Newswire
17/05/2023

Societal value of lecanemab in Japan published in Neurology and Therapy

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region and currently Eisai and BioArctic are preparing for a joint commercialization in the region. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen...
PR Newswire
17/05/2023

Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics

Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on Friday June 9, 2023 at 10.00 CEST in the premises of the company at Bryggargatan 10, Stockholm. Right to participate in the Extraordinary General Meeting and notice of participation Participation at the venue A shareholder who wishes to participate in the Meeting at the venue in person or represented by a proxy must...
Nasdaq GlobeNewswire
16/05/2023

IBT resolves on a rights issue

The Board of Directors of Infant Bacterial Therapeutics AB (publ) (“IBT” or the “Company”) has today resolved on a new issue of class A shares and class B shares of approximately SEK 100 million with preferential rights for existing shareholders (the “Rights Issue”). The purpose of the Rights Issue is to prepare IBT's lead candidate IBP-9414 for commercialization and develop the Company's early-stage projects. The Rights Issue is being carried out with a subscription price set to SEK 45 per...
Nasdaq GlobeNewswire
16/05/2023

Nyxoah Reports First Quarter 2023 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports First Quarter 2023 Financial and Operating ResultsMont-Saint-Guibert, Belgium – May 16, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2023. Recent Financial and Operating...
Nasdaq GlobeNewswire
16/05/2023

HuidaGene Therapeutics' Novel DNA Gene-Editing System Cas12i Patent Granted by…

CRISPR RNA and CRISPR-associated (Cas) protein constitute an RNA-guided adaptive immune system found in bacteria and archaea for the defense of virus infection. Class 2, Type II (CRISPR-Cas9) system has been transformed into one of the most powerful gene-editing tools used globally for biomedical research that has therapeutic potential against incurable genetic disorders by modifying their DNA sequences. However, DNA double-strand breaks (DSBs)-related genotoxicities due to formation of DSBs by…
PR Newswire
16/05/2023

Inventiva reports 2023 First Quarter Financial Information¹ and provides a…

Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million 2, and long term deposit at €9.3 million 3as of March 31, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivelyImprovements on NATiV3 Phase III clinical trial with lanifibranor in NASH with the implementation of the new design, progress in patient recruitment and recommendation, following the second meeting of the Data Monitoring Committee, to continue the trial...
Nasdaq GlobeNewswire
16/05/2023
Altri  Comunicati